Firebrick Pharma secures Philippines approval for nasal spray
- Firebrick Pharma has received approval from the Philippines Food and Drug Administration to market Nasodine Nasal Spray as an over-the-counter antiseptic drug.
- Following the regulatory update, the Firebrick Pharma share price was unchanged at $0.031.
- The company is partnering with SV More Corporation to prepare for the commercial product launch in the Philippines, targeted for early 2027.
Firebrick Pharma (ASX:FRE) has secured marketing authorisation from the Philippines Food and Drug Administration for its Nasodine Nasal Spray as an over-the-counter antiseptic drug.
This regulatory approval provides an immediate market pathway into Southeast Asia’s second-largest country, which has a population of approximately 116 million people.
"This is a long-awaited and incredibly important milestone for Firebrick and our licensing partner and strategic investor, SV More," said Firebrick Pharma Executive Chairman Dr Peter Molloy.
The initial product authorisation remains valid through Sept. 24, 2028, subject to standard post-approval documentary requirements by local distributor SV More Corporation.
The company stated that local commercial product distribution could begin as early as the first quarter of 2027.
Following the announcement, the Firebrick Pharma Limited share price was unchanged at $0.031.
Firebrick Pharma focuses on developing and commercialising its proprietary povidone-iodine nasal spray formulation to help reduce bacteria, viruses, and fungi in the nose.
The business is expanding its international footprint by securing regional drug approvals and establishing strategic distribution partnerships across global retail pharmacy markets.
